Squamous Cell Carcinoma of the Head and Neck Clinical Trials

28 recruitingLast updated: June 17, 2026

There are 28 actively recruiting squamous cell carcinoma of the head and neck clinical trials across 14 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 3. Top locations include Boston, Massachusetts, United States, Sacramento, California, United States, Barcelona, Spain. Updated daily from ClinicalTrials.gov.


Squamous Cell Carcinoma of the Head and Neck Trials at a Glance

28 actively recruiting trials for squamous cell carcinoma of the head and neck are listed on ClinicalTrialsFinder across 6 cities in 14 countries. The largest study group is Phase 2 with 16 trials, with the heaviest enrollment activity in Boston, Sacramento, and Barcelona. Lead sponsors running squamous cell carcinoma of the head and neck studies include Emory University, Mayo Clinic, and Cliniques universitaires Saint-Luc- Université Catholique de Louvain.

Browse squamous cell carcinoma of the head and neck trials by phase

Treatments under study

About Squamous Cell Carcinoma of the Head and Neck Clinical Trials

Looking for clinical trials for Squamous Cell Carcinoma of the Head and Neck? There are currently 14 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Squamous Cell Carcinoma of the Head and Neck trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Squamous Cell Carcinoma of the Head and Neck clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 28 trials

Recruiting
Phase 2

Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer

Squamous Cell Carcinoma of the Head and NeckDrug TherapyOropharynx+2 more
National Cancer Institute (NCI)70 enrolled1 locationNCT06223568
Recruiting
Phase 2

Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program

Urothelial CarcinomaEsophageal CarcinomaHepatocellular Carcinoma+28 more
Mayo Clinic50 enrolled1 locationNCT06265285
Recruiting
Phase 3

Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer

Oligometastatic Squamous Cell Carcinoma of the Head and Neck
European Organisation for Research and Treatment of Cancer - EORTC200 enrolled30 locationsNCT05815927
Recruiting
Phase 1

(89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell CarcinomaMetastatic Head and Neck Squamous Cell CarcinomaStage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck
Eben Rosenthal60 enrolled1 locationNCT05747625
Recruiting
Phase 2

5-Fluorouracil Response and Optimization STudy (The FROST Trial)

Squamous Cell Carcinoma of Head and NeckMetastatic Squamous Cell CarcinomaRecurrent Squamous Cell Carcinoma of the Head and Neck
Washington University School of Medicine46 enrolled1 locationNCT07419464
Recruiting
Not Applicable

Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation

Head and Neck Squamous Cell CarcinomaMetastatic Head and Neck Squamous Cell CarcinomaStage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8+30 more
Emory University118 enrolled1 locationNCT06662058
Recruiting
Phase 1

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

Gastric CancerEndometrial CancerHepatocellular Carcinoma+5 more
Seagen, a wholly owned subsidiary of Pfizer714 enrolled61 locationsNCT05208762
Recruiting
Phase 2

Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma

Stage II Squamous Cell Carcinoma of the Head and NeckStage III Squamous Cell Carcinoma of the Head and NeckStage IV Squamous Cell Carcinoma of the Head and Neck
National Cancer Institute (NCI)40 enrolled1 locationNCT06161545
Recruiting
Phase 2

Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC

Head and Neck Squamous Cell Carcinoma (HNSCC)Squamous Cell Carcinoma of the Head and Neck
Dana-Farber Cancer Institute32 enrolled2 locationsNCT07465276
Recruiting
Phase 1Phase 2

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Carcinoma+97 more
Mayo Clinic132 enrolled1 locationNCT05269381
Recruiting
Phase 2

Pembrolizumab for the Treatment of Locally Advanced and/or Recurrent Orbital or Periocular Cutaneous Squamous Cell Carcinoma

Recurrent Cutaneous Squamous Cell Carcinoma of the Head and NeckLocally Advanced Cutaneous Squamous Cell Carcinoma of the Head and NeckStage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
University of Michigan Rogel Cancer Center22 enrolled1 locationNCT06580054
Recruiting
Phase 1

TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer

Metastatic Head and Neck Squamous Cell CarcinomaStage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8Recurrent Head and Neck Squamous Cell Carcinoma+20 more
Emory University40 enrolled2 locationsNCT06868433
Recruiting
Phase 2

Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study

Head and Neck CarcinomaSalivary Gland CarcinomaMetastatic Malignant Neoplasm in the Lymph Nodes+9 more
Mayo Clinic174 enrolled9 locationsNCT05075980
Recruiting
Phase 1

Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer

Head and Neck CancerSolid TumorsHNSCC+10 more
VLP Therapeutics41 enrolled1 locationNCT06736379
Recruiting
Phase 1

Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

Triple-Negative Breast CancerColorectal CarcinomaNon-small Cell Lung Cancer+4 more
Janux Therapeutics130 enrolled18 locationsNCT05783622
Recruiting
Phase 1Phase 2

Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer

Triple-Negative Breast CancerSquamous Cell Carcinoma of the Head and NeckRenal Cell Cancer+1 more
Scancell Ltd168 enrolled16 locationsNCT05329532
Recruiting

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

Bladder CarcinomaEsophageal CarcinomaNon-small Cell Lung Cancer+13 more
Guardant Health, Inc.2,020 enrolled57 locationsNCT05059444
Recruiting

Identification of the Pathogenetic Mechanisms Underlying Squamous Cell Carcinomas

Squamous Cell Carcinoma of the Head and NeckSquamous Cell Carcinoma of the Anus
National Cancer Institute, Naples170 enrolled4 locationsNCT06236464
Recruiting
Phase 1

VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer

Squamous Cell Carcinoma of the Head and Neck
Emory University50 enrolled1 locationNCT03690986
Recruiting
Phase 2

Phase 2 Pragmatic Trial of Sentinel Lymph Node Biopsy (SLNB) in Patients With Clinically Node-Negative (cN0), High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) of the Head and Neck

Cutaneous Squamous Cell Carcinoma of the Head and NeckClinically Node-Negative (cN0)High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) of the Head and Neck
University of California, Davis24 enrolled1 locationNCT06990737